Summary
This study aims to evaluate the toxicity and outcomes associated with a type of radiotherapy (SABR) in participants with localised prostate cancer.
Traditional radiotherapy for prostate cancer typically involves four to eight weeks of daily treatment, Recent studies have shown that using fewer but larger doses of radiation, i.e. 5-treatment SABR, is just as effective and safe, and this has now become one of the standard radiotherapy schedules.
Researchers want to know whether they can further reduce the number of treatments for prostate SABR while maintaining the cancer control rate and minimising side effects.
You may be eligible to join this study if you are aged 18 years or above, and have intermediate risk localised prostate cancer with no histological evidence of nodal or distant metastatic disease. Participants will recieve radiotherapy in 2 fractions, one week apart.